Interim results (2-year) of a French non-interventional study to assess the long-term safety and efficacy of BeneFIX

被引：0
|
作者：
Rothschild, C. [1 ]
Trossaert, M. [2 ]
Claeyssens, S. [3 ]
Lambert, T. [4 ]
Hassoun, A. [5 ]
Volot, F. [6 ]
Dubanchet, A. [7 ]
机构：
[1] Necker AP HP Hosp, Hemophilia Treatment Ctr, Paris, France
[2] Hop Hotel Dieu, Hemophilia Treatment Ctr, Nantes, France
[3] Purpan Hosp, Hemophilia Treatment Ctr, Toulouse, France
[4] Bicetre AP HP Hosp, Hemophilia Treatment Ctr, Le Kremlin Bicetre, France
[5] Simone Veil Hosp, Hemophilia Treatment Ctr, Montmorency Foret, France
[6] Bocage Hosp, Hemophilia Treatment Ctr, Dijon, France
[7] Pfizer, Paris, France
来源：
HAEMOPHILIA | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：23 / 24
页数：2
相关论文
共 50 条
  • [1] Interim results (3-year) of a French non-interventional study to assess the long-term safety and efficacy of BeneFIX
    Rothschild, C.
    Trossaert, M.
    Claeyssens-Donadel, S.
    Lambert, T.
    Hassoun, A.
    Volot, F.
    Attal, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 428 - 428
  • [2] Four-year interim results of a non-interventional trial to assess the safety and efficacy of treatment with recombinant factor IX, BeneFIX®
    Hardewig, J.
    Oldenburg, J.
    Pollmann, H.
    HAEMOPHILIA, 2012, 18 : 24 - 24
  • [3] Two-year interim results of a non-interventional trial to assess the safety and efficacy of treatment with recombinant factor IX
    Westfeld, M.
    Pollmann, H.
    Oldenburg, J.
    HAEMOPHILIA, 2010, 16 : 32 - 32
  • [4] Efficacy and safety of tirbanibulin in actinic keratoses. Interim results of a non-interventional study
    Heppt, M.
    Hadshiew, I.
    Kempf, A.
    Melzer, A.
    Berking, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 69 - 70
  • [5] Fremanezumab Long-Term Efficacy and Safety: Interim Results of a One-Year Study
    Goadsby, P.
    Yeung, P. P.
    Blankenbiller, T.
    Grozinski-Wolff, M.
    Yang, R.
    Ma, Y.
    Ning, X.
    Aycardi, E.
    HEADACHE, 2018, 58 : 166 - 166
  • [6] LONG-TERM SAFETY OF ADALIMUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: INTERIM RESULTS OF A NON-INTERVENTIONAL REGISTRY, LEGACY
    Bossuyt, Peter
    Atreya, Raja
    Samso, Carlos Taxonera
    Hebuterne, Xavier
    Isaacs, Kim
    Higgins, Peter D.
    Lindsay, James O.
    Heap, Graham
    Arikan, Dilek
    Kuehnl, Vera
    Petersson, Joel H.
    Robinson, Anne M.
    Loftus, Edward V.
    GASTROENTEROLOGY, 2018, 154 (06) : S829 - S829
  • [7] Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY
    Bossuyt, P.
    Atreya, R.
    Taxonera, C.
    Hebuterne, X.
    Isaacs, K.
    Higgins, P. D.
    Lindsay, J.
    Heap, G.
    Arikan, D.
    Kuehnl, V.
    Petersson, J.
    Robinson, A. M.
    Loftus, E. V., Jr.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S32 - S32
  • [8] Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
    Santos, Raul D.
    Duell, P. Barton
    East, Cara
    Guyton, John R.
    Moriarty, Patrick M.
    Chin, Wai
    Mittleman, Robert S.
    EUROPEAN HEART JOURNAL, 2015, 36 (09) : 566 - 575
  • [9] LONG-TERM SAFETY AND EFFICACY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC): 2-YEAR RESULTS FROM A LONG-TERM STUDY
    Mayo, Marlyn J.
    Vierling, John M.
    Bowlus, Christopher L.
    Neff, Guy W.
    Galambos, Michael R.
    Gordon, Stuart C.
    Borg, Brian
    Levy, Cynthia
    Harrison, Stephen A.
    Thuluvath, Paul J.
    Goel, Aparna
    Shiffman, Mitchell L.
    Steinberg, Alexandra
    Xu, Emily
    Yang, Ke
    Choi, Yun-Jung
    Dickinson, Klara
    McWherter, Charles
    HEPATOLOGY, 2021, 74 : 71A - 73A
  • [10] NON-INTERVENTIONAL POST-MARKETING SAFETY STUDY ON THE LONG-TERM SAFETY OF HYQVIA (GLOBAL)
    Fielhauer, Katharina
    Nagy, Andras
    Rabbat, Christopher
    McCoy, Barbara
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (03) : 268 - 268
12345